Replies to post #203281 on Biotech Values

[DewDiligence]

ENTA had $242.2M cash at 9/30/16 (a slight decrease of $2.5M relative to 6/30/16):

http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2225023

GAAP EPS for the fiscal year ending 9/30/16 was $1.13.

ENTA expects FY2017 R&D of $50-60M (compared to $40.5M during FY2016) due to increased spending on ENTA’s wholly-owned EDP-305 and EDP-494 programs.